AU2007249160B2 - Neutralizing antibodies to influenza viruses - Google Patents

Neutralizing antibodies to influenza viruses Download PDF

Info

Publication number
AU2007249160B2
AU2007249160B2 AU2007249160A AU2007249160A AU2007249160B2 AU 2007249160 B2 AU2007249160 B2 AU 2007249160B2 AU 2007249160 A AU2007249160 A AU 2007249160A AU 2007249160 A AU2007249160 A AU 2007249160A AU 2007249160 B2 AU2007249160 B2 AU 2007249160B2
Authority
AU
Australia
Prior art keywords
antibody
influenza
antibodies
virus
libraries
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007249160A
Other languages
English (en)
Other versions
AU2007249160A1 (en
Inventor
Ramesh R. Bhatt
Lawrence Horowitz
Arun K. Kashyap
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
I2 Pharmaceuticals Inc
Original Assignee
I2 Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I2 Pharmaceuticals Inc filed Critical I2 Pharmaceuticals Inc
Publication of AU2007249160A1 publication Critical patent/AU2007249160A1/en
Assigned to SEA LANE BIOTECHNOLOGIES, LLC reassignment SEA LANE BIOTECHNOLOGIES, LLC Alteration of Name(s) of Applicant(s) under S113 Assignors: SEA LANE BIOTECHNOLOGIES, LLC.
Application granted granted Critical
Publication of AU2007249160B2 publication Critical patent/AU2007249160B2/en
Assigned to I2 PHARMACEUTICALS, INC. reassignment I2 PHARMACEUTICALS, INC. Request for Assignment Assignors: SEA LANE BIOTECHNOLOGIES, LLC
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2007249160A 2006-05-15 2007-05-15 Neutralizing antibodies to influenza viruses Ceased AU2007249160B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80078706P 2006-05-15 2006-05-15
US60/800,787 2006-05-15
US85567906P 2006-10-30 2006-10-30
US60/855,679 2006-10-30
PCT/US2007/068983 WO2007134327A2 (en) 2006-05-15 2007-05-15 Neutralizing antibodies to influenza viruses

Publications (2)

Publication Number Publication Date
AU2007249160A1 AU2007249160A1 (en) 2007-11-22
AU2007249160B2 true AU2007249160B2 (en) 2013-09-12

Family

ID=38694784

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007249160A Ceased AU2007249160B2 (en) 2006-05-15 2007-05-15 Neutralizing antibodies to influenza viruses

Country Status (8)

Country Link
US (4) US20080014205A1 (https=)
EP (2) EP2024393A2 (https=)
JP (2) JP2009537147A (https=)
CN (1) CN103435697A (https=)
AU (1) AU2007249160B2 (https=)
CA (1) CA2652452C (https=)
IL (3) IL195225A (https=)
WO (1) WO2007134327A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
WO2008110937A2 (en) * 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus
BRPI0809435A2 (pt) 2007-03-27 2014-09-09 Sea Lane Biotechnologies, Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
EP2144617A4 (en) * 2007-04-11 2011-04-27 Immuron Ltd RELEASE OF GRIP ANTIBODIES ON SURFACES IN CONTACT WITH AIR
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
ITTO20080204A1 (it) * 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
WO2009121004A2 (en) * 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
WO2010010467A2 (en) * 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
GB0818356D0 (en) * 2008-10-07 2008-11-12 Istituto Superiore Di Sanito Antibodies
US20110195079A1 (en) * 2008-10-21 2011-08-11 Dormitzer Philip Immunization protocol for directed expansion and maturation
BRPI0914092B1 (pt) 2008-10-22 2021-08-31 Institute For Research In Biomedicine Método de produção de um anticorpo a partir de células plasmáticas, método de produção de um anticorpo monoclonal a partir de células plasmáticas e método de produção de um anticorpo ou de um fragmento de anticorpo
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
AU2010247530B2 (en) * 2009-05-11 2016-10-13 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
AU2010254136B2 (en) * 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
CA2790380A1 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
ES2687706T3 (es) * 2010-06-17 2018-10-26 Trellis Bioscience, Llc Anticuerpos útiles en la inmunización pasiva contra la gripe
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
EP2436766A1 (en) * 2010-09-29 2012-04-04 Deutsches Krebsforschungszentrum Means and methods for improved protein interaction screening
WO2012045001A2 (en) * 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
EP2640831A1 (en) * 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
HRP20190714T1 (hr) 2011-07-18 2019-06-14 Institute For Research In Biomedicine Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
WO2013016714A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
IN2014CN02114A (https=) 2011-09-20 2015-05-29 Sinai School Medicine
MX350282B (es) 2011-09-30 2017-09-01 Celltrion Inc Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas.
KR20130059721A (ko) * 2011-11-29 2013-06-07 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
ES2686526T3 (es) 2011-12-05 2018-10-18 Trellis Bioscience, Llc Anticuerpos útiles en la inmunización pasiva contra la influenza
KR101749316B1 (ko) * 2011-12-15 2017-06-21 (주) 에이프로젠 Ｈ１ｎ１―감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
EP3446707A1 (en) 2011-12-22 2019-02-27 i2 Pharmaceuticals, Inc. Surrogate binding proteins
SG11201404653UA (en) * 2012-02-07 2014-09-26 Univ Pittsburgh Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
EA201591164A1 (ru) 2012-12-18 2015-11-30 Икан Скул Оф Медсин Эт Маунт Синай Вакцины против вируса гриппа и их применение
US11827693B2 (en) 2013-03-14 2023-11-28 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
US9101597B2 (en) 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3037533A4 (en) 2013-08-23 2017-07-05 Fujita Health University Anti-influenza virus-neutralizing antibody
EP3733244A1 (en) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof
TWI712421B (zh) 2013-11-11 2020-12-11 日商中外製藥股份有限公司 含改變的抗體可變區之抗原結合分子
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP6712428B2 (ja) 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
EP3126384B1 (en) * 2014-04-01 2020-12-02 Adimab, LLC Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
CN119161468A (zh) 2014-07-15 2024-12-20 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
TWI880146B (zh) 2014-11-11 2025-04-11 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
CN113480640B (zh) 2015-06-01 2024-07-30 免疫医疗有限责任公司 中和抗流感结合分子及其用途
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2017123685A1 (en) 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
CA3023143A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
GB201614485D0 (en) * 2016-08-25 2016-10-12 Univ Oxford Innovation Ltd Immunogenic composition
DK3532612T3 (da) 2016-10-31 2022-09-19 Univ Zuerich Samling af markører og fremgangsmåder til proteindetektion, fortrinsvis ved massespektrometri
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
US11434277B2 (en) 2017-10-20 2022-09-06 Academia Sinica Method for high-throughput screening of neutralizing antibodies, neutralizing antibodies produced therefrom, and uses thereof
TW201938194A (zh) * 2017-12-05 2019-10-01 日商中外製藥股份有限公司 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
MX2021000827A (es) 2018-08-03 2021-03-25 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno que contiene dos dominios de union a antigeno que estan enlazados entre si.
BR112021005472A2 (pt) 2018-09-28 2021-06-15 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno compreendendo uma região variável do anticorpo alterada
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
EP3959216A4 (en) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
US20220267382A1 (en) * 2019-09-20 2022-08-25 Academia Sinica Chimeric hemagglutinin protein and a vaccine composition comprising the same
TWI909146B (zh) 2020-03-31 2025-12-21 日商中外製藥股份有限公司 Dll3靶向之多特異性抗原結合分子及其用途
CN113121680B (zh) * 2021-04-12 2022-03-29 华南农业大学 一种抗h5亚型禽流感纳米抗体蛋白及其编码基因与应用
CN113355344B (zh) * 2021-08-10 2021-11-02 北京溯本源和生物科技有限公司 一种流感病毒ns1蛋白的表达质粒、重组蛋白和特异性单克隆抗体及应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984000687A1 (en) * 1982-08-23 1984-03-01 Scripps Clinic Res Broad spectrum influenza antisera
WO1996007754A1 (en) * 1994-09-02 1996-03-14 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
WO2000057183A1 (en) * 1999-03-23 2000-09-28 Biovation Limited Protein isolation and analysis
US20020054882A1 (en) * 1992-09-17 2002-05-09 Yoshinobu Okuno Anti-human influenza virus antibody
WO2002046235A1 (fr) * 2000-12-07 2002-06-13 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
WO2002061071A2 (en) * 2000-12-18 2002-08-08 Dyax Corp. Focused libraries of genetic packages
WO2003078600A2 (en) * 2002-03-13 2003-09-25 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
WO2003092630A2 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
WO2005042759A2 (en) * 2003-09-10 2005-05-12 Althea Technologies, Inc. Expression profiling using microarrays
AU2006290736A1 (en) * 2005-09-15 2007-03-22 Crucell Holland B.V. Method for preparing immunoglobulin libraries
WO2007089753A2 (en) * 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3852304T3 (de) 1987-03-02 1999-07-01 Enzon Labs Inc., Piscataway, N.J. Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
ATE144281T1 (de) 1989-04-28 1996-11-15 Rhein Biotech Proz & Prod Gmbh Hefezellen der gattung-schwanniomyces
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2078518T3 (es) 1990-04-05 1995-12-16 Roberto Crea Mutagenesis por desplazamiento completo.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
JP3037554B2 (ja) * 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
US20030194807A1 (en) 1992-11-02 2003-10-16 Roberto Crea Walk-through mutagenesis
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
DE60328674D1 (de) 2002-04-17 2009-09-17 Bioren Inc Universelle banken für immunoglobuline
AU2004254352A1 (en) 2003-06-27 2005-01-13 Roberto Crea Look-through mutagenesis
EP1851238A4 (en) * 2005-02-24 2008-12-31 Univ Massachusetts FLUID NUCLEIC ACIDS, POLYPEPTIDES AND USES THEREOF
GB0522460D0 (en) * 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984000687A1 (en) * 1982-08-23 1984-03-01 Scripps Clinic Res Broad spectrum influenza antisera
US20020054882A1 (en) * 1992-09-17 2002-05-09 Yoshinobu Okuno Anti-human influenza virus antibody
WO1996007754A1 (en) * 1994-09-02 1996-03-14 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
WO2000057183A1 (en) * 1999-03-23 2000-09-28 Biovation Limited Protein isolation and analysis
WO2002046235A1 (fr) * 2000-12-07 2002-06-13 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
WO2002061071A2 (en) * 2000-12-18 2002-08-08 Dyax Corp. Focused libraries of genetic packages
WO2003078600A2 (en) * 2002-03-13 2003-09-25 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
WO2003092630A2 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
WO2005042759A2 (en) * 2003-09-10 2005-05-12 Althea Technologies, Inc. Expression profiling using microarrays
AU2006290736A1 (en) * 2005-09-15 2007-03-22 Crucell Holland B.V. Method for preparing immunoglobulin libraries
WO2007089753A2 (en) * 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Knappik, A. et al (2000) J. Mol. Biol., 296:57-86 *
Rimmelzwaan, G. F. et al (1999) Vaccine, 17:2512-2516 *
Smirnov, Y. A. et al (1999) Acta Virol., 43:237-244 *
Smirnov, Y. A. et al (2000) Arch. Virol., 145:1733-1741 *
Stephenson, I. et al (2005) J. Infect. Dis., 191:1210-1215 *

Also Published As

Publication number Publication date
IL195225A (en) 2015-06-30
CA2652452A1 (en) 2007-11-22
IL222762A0 (en) 2012-12-31
JP2009537147A (ja) 2009-10-29
EP2522678A1 (en) 2012-11-14
US20100316654A1 (en) 2010-12-16
IL239023A0 (en) 2015-07-30
IL195225A0 (en) 2011-08-01
CA2652452C (en) 2018-07-31
US20120107326A1 (en) 2012-05-03
WO2007134327A2 (en) 2007-11-22
US20080014205A1 (en) 2008-01-17
EP2024393A2 (en) 2009-02-18
US20140205614A1 (en) 2014-07-24
WO2007134327A3 (en) 2008-10-02
CN103435697A (zh) 2013-12-11
AU2007249160A1 (en) 2007-11-22
JP2013067660A (ja) 2013-04-18

Similar Documents

Publication Publication Date Title
AU2007249160B2 (en) Neutralizing antibodies to influenza viruses
US10017561B2 (en) Neutralizing molecules to influenza viruses
US9169318B2 (en) Neutralizing molecules to viral antigens
US8148085B2 (en) Donor specific antibody libraries
CN101495511A (zh) 流感病毒的中和抗体
HK1133895A (en) Neutralizing antibodies to influenza viruses
HK1192256A (en) Neutralizing antibodies to influenza viruses
HK1195318A (en) Neutralizing molecules to viral antigens

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: I2 PHARMACEUTICALS, INC.

Free format text: FORMER OWNER(S): SEA LANE BIOTECHNOLOGIES, LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired